NATURE . COM {}

Analyzed Page
Matching Content Categories
CMS
Monthly Traffic Estimate
How Does Nature.com Make Money
How Much Does Nature.com Make
Keywords
Topics
Schema
Social Networks
External Links
Analytics And Tracking
Libraries
Hosting Providers

We are analyzing https://www.nature.com/articles/6601306.

Title:
A phase II trial with rosiglitazone in liposarcoma patients | British Journal of Cancer
Description:
Agents of the thiazolidinedione drug family can terminally differentiate human liposarcoma cells in vitro by activating genes responsible for lipocyte differentiation. One study has shown clinical activity of troglitazone treatment in liposarcoma patients. We sought to find further evidence for this result. In all, 12 patients with a liposarcoma received rosiglitazone 4 mg b.d. They were followed clinically and with repeated biopsies for histological and biological studies. At the molecular level the mRNA translation of three genes that are induced by this treatment (peroxisome proliferator-activated receptor γ (PPARγ), adipsin and fatty acid binding protein) was determined. Nine patients were eligible for evaluation. One patient had to stop treatment due to hepatotoxicity. The mean time to progression was 6 months (2 – 16 months), with one patient still on treatment. We did not see any significant change in histologic appearance of the liposarcomas by the treatment. The level of gene expression changed significantly in two patients, but this did not result in a clinical response. Based on this study, rosiglitazone is not effective as an antitumoral drug in the treatment of liposarcomas. Increased PPARγ activity does not correlate with the clinical evolution.
Website Age:
30 years and 10 months (reg. 1994-08-11).

Matching Content Categories {📚}

Science
Education
Health & Fitness

Content Management System {📝}

What CMS is nature.com built with?

Custom-built

No common CMS systems were detected on Nature.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of nature.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Nature.com Make Money? {💸}

Display Ads {🎯}

The website utilizes display ads within its content to generate revenue. Check the next section for further revenue estimates.

Ads are managed by yourbow.com. Particular relationships are as follows:

Direct Advertisers (10)

google.com, pmc.com, doceree.com, yourbow.com, audienciad.com, onlinemediasolutions.com, advibe.media, aps.amazon.com, getmediamx.com, onomagic.com

Reseller Advertisers (38)

conversantmedia.com, rubiconproject.com, pubmatic.com, appnexus.com, openx.com, smartadserver.com, lijit.com, sharethrough.com, video.unrulymedia.com, google.com, yahoo.com, triplelift.com, onetag.com, sonobi.com, contextweb.com, 33across.com, indexexchange.com, media.net, themediagrid.com, adform.com, richaudience.com, sovrn.com, improvedigital.com, freewheel.tv, smaato.com, yieldmo.com, amxrtb.com, adyoulike.com, adpone.com, criteo.com, smilewanted.com, 152media.info, e-planning.net, smartyads.com, loopme.com, opera.com, mediafuse.com, betweendigital.com

How Much Does Nature.com Make? {💰}

Display Ads {🎯}

$63,100 per month
Our estimates place Nature.com's monthly online earnings from display ads at $42,042 to $115,616.

Keywords {🔍}

patients, liposarcoma, pparγ, treatment, pubmed, article, google, scholar, cancer, cas, nature, rosiglitazone, clinical, liposarcomas, human, expression, patient, gene, differentiation, molecular, peroxisome, proliferatoractivated, receptor, tumour, cells, study, months, cell, tontonoz, gamma, analysis, data, troglitazone, spiegelman, leuven, level, fletcher, cookies, content, trial, genes, biological, adipsin, protein, myxoid, fusion, activation, performed, probe, privacy,

Topics {✒️}

nature portfolio privacy policy peroxisome proliferator-activated receptor-γ peroxisome-proliferator activated receptor-gamma advertising nature 363 nature soft-tissue sarcoma—gold standard social media peroxisome proliferator-activated receptors author information authors 0/ reprints lipid-activated transcription factor pax8-ppargamma1 fusion oncogene author correspondence tls-chop fusion protein ews-chop fusion transcript ultrasound-guided needle biopsy full size image permissions myxoid/round cell subtypes inhibit tumour growth myxoid/round cell liposarcomas high affinity ligand soft tissue simulators privacy 14 october 2003 rna-binding protein primary tumour sample dei tos utilising standard procedures explore content tissue-specific regulator journals search log solid tumor differentiation human colon cancer metastastic colon cancer van den bh human myxoid liposarcoma round cell liposarcoma cellular proliferation rates european economic area personal data meis-kindblom giant marker chromosomes chromosomal region 12q spring-driven device quantify mrna levels glyceraldehyde-3-phosphate dehydrogenase g-banded chromosomes

Schema {🗺️}

WebPage:
      mainEntity:
         headline:A phase II trial with rosiglitazone in liposarcoma patients
         description:Agents of the thiazolidinedione drug family can terminally differentiate human liposarcoma cells in vitro by activating genes responsible for lipocyte differentiation. One study has shown clinical activity of troglitazone treatment in liposarcoma patients. We sought to find further evidence for this result. In all, 12 patients with a liposarcoma received rosiglitazone 4âmg b.d. They were followed clinically and with repeated biopsies for histological and biological studies. At the molecular level the mRNA translation of three genes that are induced by this treatment (peroxisome proliferator-activated receptor Î³ (PPARÎ³), adipsin and fatty acid binding protein) was determined. Nine patients were eligible for evaluation. One patient had to stop treatment due to hepatotoxicity. The mean time to progression was 6 months (2âââ16 months), with one patient still on treatment. We did not see any significant change in histologic appearance of the liposarcomas by the treatment. The level of gene expression changed significantly in two patients, but this did not result in a clinical response. Based on this study, rosiglitazone is not effective as an antitumoral drug in the treatment of liposarcomas. Increased PPARÎ³ activity does not correlate with the clinical evolution.
         datePublished:2003-10-14T00:00:00Z
         dateModified:2011-11-16T00:00:00Z
         pageStart:1409
         pageEnd:1412
         sameAs:https://doi.org/10.1038/sj.bjc.6601306
         keywords:
            liposarcoma
            rosiglitazone
            PPARÎ³
            Biomedicine
            general
            Cancer Research
            Epidemiology
            Molecular Medicine
            Oncology
            Drug Resistance
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.bjc.6601306/MediaObjects/41416_2003_Article_BF6601306_Fig1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.bjc.6601306/MediaObjects/41416_2003_Article_BF6601306_Fig2_HTML.jpg
         isPartOf:
            name:British Journal of Cancer
            issn:
               1532-1827
               0007-0920
            volumeNumber:89
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Nature Publishing Group UK
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:G Debrock
               affiliation:
                     name:University Hospital Gasthuisberg, Universiteit Leuven
                     address:
                        name:Department of Medical Oncology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:V Vanhentenrijk
               affiliation:
                     name:University Hospital Gasthuisberg, Universiteit Leuven
                     address:
                        name:Department of Pathology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
                        type:PostalAddress
                     type:Organization
               type:Person
               name:R Sciot
               affiliation:
                     name:University Hospital Gasthuisberg, Universiteit Leuven
                     address:
                        name:Department of Pathology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
                        type:PostalAddress
                     type:Organization
               type:Person
               name:M Debiec-Rychter
               affiliation:
                     name:University Hospital Gasthuisberg, Universiteit Leuven
                     address:
                        name:Department of Human Genetics, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
                        type:PostalAddress
                     type:Organization
               type:Person
               name:R Oyen
               affiliation:
                     name:University Hospital Gasthuisberg, Universiteit Leuven
                     address:
                        name:Department of Radiology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
                        type:PostalAddress
                     type:Organization
               type:Person
               name:A Van Oosterom
               affiliation:
                     name:University Hospital Gasthuisberg, Universiteit Leuven
                     address:
                        name:Department of Medical Oncology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:A phase II trial with rosiglitazone in liposarcoma patients
      description:Agents of the thiazolidinedione drug family can terminally differentiate human liposarcoma cells in vitro by activating genes responsible for lipocyte differentiation. One study has shown clinical activity of troglitazone treatment in liposarcoma patients. We sought to find further evidence for this result. In all, 12 patients with a liposarcoma received rosiglitazone 4âmg b.d. They were followed clinically and with repeated biopsies for histological and biological studies. At the molecular level the mRNA translation of three genes that are induced by this treatment (peroxisome proliferator-activated receptor Î³ (PPARÎ³), adipsin and fatty acid binding protein) was determined. Nine patients were eligible for evaluation. One patient had to stop treatment due to hepatotoxicity. The mean time to progression was 6 months (2âââ16 months), with one patient still on treatment. We did not see any significant change in histologic appearance of the liposarcomas by the treatment. The level of gene expression changed significantly in two patients, but this did not result in a clinical response. Based on this study, rosiglitazone is not effective as an antitumoral drug in the treatment of liposarcomas. Increased PPARÎ³ activity does not correlate with the clinical evolution.
      datePublished:2003-10-14T00:00:00Z
      dateModified:2011-11-16T00:00:00Z
      pageStart:1409
      pageEnd:1412
      sameAs:https://doi.org/10.1038/sj.bjc.6601306
      keywords:
         liposarcoma
         rosiglitazone
         PPARÎ³
         Biomedicine
         general
         Cancer Research
         Epidemiology
         Molecular Medicine
         Oncology
         Drug Resistance
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.bjc.6601306/MediaObjects/41416_2003_Article_BF6601306_Fig1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.bjc.6601306/MediaObjects/41416_2003_Article_BF6601306_Fig2_HTML.jpg
      isPartOf:
         name:British Journal of Cancer
         issn:
            1532-1827
            0007-0920
         volumeNumber:89
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Nature Publishing Group UK
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:G Debrock
            affiliation:
                  name:University Hospital Gasthuisberg, Universiteit Leuven
                  address:
                     name:Department of Medical Oncology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:V Vanhentenrijk
            affiliation:
                  name:University Hospital Gasthuisberg, Universiteit Leuven
                  address:
                     name:Department of Pathology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
                     type:PostalAddress
                  type:Organization
            type:Person
            name:R Sciot
            affiliation:
                  name:University Hospital Gasthuisberg, Universiteit Leuven
                  address:
                     name:Department of Pathology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
                     type:PostalAddress
                  type:Organization
            type:Person
            name:M Debiec-Rychter
            affiliation:
                  name:University Hospital Gasthuisberg, Universiteit Leuven
                  address:
                     name:Department of Human Genetics, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
                     type:PostalAddress
                  type:Organization
            type:Person
            name:R Oyen
            affiliation:
                  name:University Hospital Gasthuisberg, Universiteit Leuven
                  address:
                     name:Department of Radiology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
                     type:PostalAddress
                  type:Organization
            type:Person
            name:A Van Oosterom
            affiliation:
                  name:University Hospital Gasthuisberg, Universiteit Leuven
                  address:
                     name:Department of Medical Oncology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:British Journal of Cancer
      issn:
         1532-1827
         0007-0920
      volumeNumber:89
Organization:
      name:Nature Publishing Group UK
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University Hospital Gasthuisberg, Universiteit Leuven
      address:
         name:Department of Medical Oncology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
         type:PostalAddress
      name:University Hospital Gasthuisberg, Universiteit Leuven
      address:
         name:Department of Pathology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
         type:PostalAddress
      name:University Hospital Gasthuisberg, Universiteit Leuven
      address:
         name:Department of Pathology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
         type:PostalAddress
      name:University Hospital Gasthuisberg, Universiteit Leuven
      address:
         name:Department of Human Genetics, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
         type:PostalAddress
      name:University Hospital Gasthuisberg, Universiteit Leuven
      address:
         name:Department of Radiology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
         type:PostalAddress
      name:University Hospital Gasthuisberg, Universiteit Leuven
      address:
         name:Department of Medical Oncology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:G Debrock
      affiliation:
            name:University Hospital Gasthuisberg, Universiteit Leuven
            address:
               name:Department of Medical Oncology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:V Vanhentenrijk
      affiliation:
            name:University Hospital Gasthuisberg, Universiteit Leuven
            address:
               name:Department of Pathology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
               type:PostalAddress
            type:Organization
      name:R Sciot
      affiliation:
            name:University Hospital Gasthuisberg, Universiteit Leuven
            address:
               name:Department of Pathology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
               type:PostalAddress
            type:Organization
      name:M Debiec-Rychter
      affiliation:
            name:University Hospital Gasthuisberg, Universiteit Leuven
            address:
               name:Department of Human Genetics, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
               type:PostalAddress
            type:Organization
      name:R Oyen
      affiliation:
            name:University Hospital Gasthuisberg, Universiteit Leuven
            address:
               name:Department of Radiology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
               type:PostalAddress
            type:Organization
      name:A Van Oosterom
      affiliation:
            name:University Hospital Gasthuisberg, Universiteit Leuven
            address:
               name:Department of Medical Oncology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Medical Oncology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
      name:Department of Pathology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
      name:Department of Pathology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
      name:Department of Human Genetics, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
      name:Department of Radiology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium
      name:Department of Medical Oncology, University Hospital Gasthuisberg, Universiteit Leuven, Leuven, Belgium

Social Networks {👍}(1)

https://twitter.com/BrJCancer

External Links {🔗}(83)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Prism.js
Zoom.js

Emails and Hosting {✉️}

Mail Servers:

mxa-002c5801.gslb.pphosted.com
mxb-002c5801.gslb.pphosted.com

Name Servers:

pdns1.ultradns.net
pdns2.ultradns.net
pdns3.ultradns.org
pdns4.ultradns.org
pdns5.ultradns.info
pdns6.ultradns.co.uk

4.69s.